Novel Antibody-Drug Conjugate Shows Efficacy in Advanced EGFR-Mutated NSCLC
(MedPage Today) -- SINGAPORE -- Treatment with the novel antibody-drug conjugate patritumab deruxtecan (HER3-DXd) after progression with an EGFR tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy resulted in "clinically meaningful...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news
More News: Cancer & Oncology | Chemotherapy | Hematology | Non-Small Cell Lung Cancer | Singapore Health